Name: ABSA’s 1st Biosecurity Symposium
Start: 2021-04-20T00:00:00-05:00
End: 2021-04-23T23:59:59-05:00
Location: Renaissance Depot Hotel

Human Spillover Potential of Reston Ebolavirus Noted by NIAID Study

The Coping Mechanisms the DRC is Putting in Place As it Faces Ebola, Measles and COVID-19

by Yap Boum, Mbarara University of Science and Technology June 22, 2020, 9:26 am
FDA Accepts for Priority Review for REGN-EB3 to Treat Ebola

by Global Biodefense Staff April 16, 2020, 4:03 pm
New Universal Ebola Vaccine May Fight All Four Virus Species that Infect Humans

by Global Biodefense Staff April 16, 2020, 11:15 am
Soligenix Announces Successful Demonstration of Heat Stabilization for Filovirus Vaccine Platform

by Global Biodefense Staff March 3, 2020, 6:04 pm
Health Security Today – 27 Feb 2020

by Global Biodefense Staff February 27, 2020, 1:00 am
U.S. Ebola Treatment Center Costs and Sustainability if Federal Funding Withdrawn

by Global Biodefense Staff February 25, 2020, 11:33 pm
Ebola Still Constitutes a Public Health Emergency of International Concern

by Global Biodefense Staff February 16, 2020, 12:04 pm
New Method Predicts Individual Response to Ebola Infection

by Global Biodefense Staff February 16, 2020, 10:05 am
Scientists Find Ally in Fight Against Brain Tumors: Ebola

by Global Biodefense Staff February 16, 2020, 10:01 am
Antibody Mixture May Help Block Ebola Virus Infection

by Global Biodefense Staff February 6, 2020, 1:46 pm
HHS, Regeneron Collaborate to Develop COVID-19 Treatment Using VelociSuite Technology

by Global Biodefense Staff February 4, 2020, 8:44 pm
Newsletter

Global Biodefense News

First Name

Last Name

Organization Type

Email address:

Don't worry, we don't spam
First-Ever Therapeutic Antibody Cocktail for Sudan Virus Shows Promise in Animal Studies

by Global Biodefense Staff February 4, 2020, 4:22 pm
Boston Hospital Only New England Center Designated to Treat Ebola Patients

by Global Biodefense Staff January 22, 2020, 10:08 pm
MSF Update on Ebola Frontline Response

by Global Biodefense Staff January 20, 2020, 1:22 pm

Congratulations. You've reached the end of the internet.

Ebola

Human Spillover Potential of Reston Ebolavirus Noted by NIAID Study

Ebola Outbreak in the Democratic Republic of the Congo Ends

Targeting the Shell of the Ebola Virus for a Knock-Out with Antivirals

FDA Approves First Ebola Therapeutic

The Coping Mechanisms the DRC is Putting in Place As it Faces Ebola, Measles and COVID-19

FDA Accepts for Priority Review for REGN-EB3 to Treat Ebola

New Universal Ebola Vaccine May Fight All Four Virus Species that Infect Humans

Soligenix Announces Successful Demonstration of Heat Stabilization for Filovirus Vaccine Platform

Health Security Today – 27 Feb 2020

U.S. Ebola Treatment Center Costs and Sustainability if Federal Funding Withdrawn

Ebola Still Constitutes a Public Health Emergency of International Concern

New Method Predicts Individual Response to Ebola Infection

Scientists Find Ally in Fight Against Brain Tumors: Ebola

Antibody Mixture May Help Block Ebola Virus Infection

HHS, Regeneron Collaborate to Develop COVID-19 Treatment Using VelociSuite Technology

First-Ever Therapeutic Antibody Cocktail for Sudan Virus Shows Promise in Animal Studies

Boston Hospital Only New England Center Designated to Treat Ebola Patients

MSF Update on Ebola Frontline Response

Biodefense Headlines – 21 January 2021

First Cases of B.1.1.7 Variant COVID-19 Detected in Washington State

The Response Measures Database: Central Archive of COVID-19 Interventions

EU Initiative on Health Security Work Programme 2021

Rapid Identification of Ricin in Serum Samples Using LC–MS/MS

Dr. Fauci Makes First Appearance at Biden White House Press Briefing – Transcript

ASM Expresses Support for the Global Health Security Act of 2021

How and When Will Lower-Income Countries Gain Access to COVID-19 Vaccines?

OHDSI Awarded $10M FDA Contract to Monitor Safety and Effectiveness of Vaccines, Biologics

Neutralizing Norovirus: NIAID Monoclonal Antibodies Licensing Opportunity

NIAID Looks Ahead to Pan-Coronavirus Vaccine Candidates

DRIVE ReDIRECT: Program Seeks to Develop Countermeasures Against Chemical Threats

Emerging Infections Network – Managing Travelers Who Acquire Disease Abroad

Upcoming Events

Application Deadline: Expanding Existing Research Grants, CRADAs for Novel Coronavirus Response

Envisioning a Transformed Clinical Trials Enterprise for 2030 – Session 2

Systematizing the One Health Approach in Preparedness and Response Efforts for Infectious Disease Outbreaks

Envisioning a Transformed Clinical Trials Enterprise for 2030 – Session 3

ABSA’s 1st Biosecurity Symposium

Latest stories

Latest Articles